Breast Surgeons Live

 Back to Activities List

Session Title:
Ongoing Clinical Trial Updates
Date & Time:
February 20, 2024, 7:00 PM–8:00 PM ET
1 Hour
CME Deadline:
February 20, 2025
Log in to access members-only content.
Target Audience:
Surgeons with a special interest in the treatment of breast disease.
At the end of this activity, participants will be able to:
  • Critically review recently reported clinical trials on breast cancer management.
  • Understand the implications of data from recently reported clinical trials for multidisciplinary breast practice.
  • Develop and discuss questions pertaining to incorporation of these new data into clinical practice
Review recently reported clinical trials and implications for clinical multidisciplinary breast practice.
Local Regional Trials
Mediget Teshome, MD, FACS
  • Sound (Jama Oncology 2023)
  • NSABP B51 (SABCS 2023)
  • IDEA (JCO 2024)
  • Alliance Z11102 (JCO 2023)
Systemic Therapy Trials
Rebecca Shatsky, MD
  • Katherine update (SABCS 2023)
  • Keynote 522 (NEJM 2022) & Currently accruing TNBC trials (ASCENT-05)
Hal Burstein, MD, PhD
  • NATALEE (SABCS 2023)
  • Positive trial (NEJM 2023)
Moderator—Jane E. Mendez, MD, FACS
Miami Cancer Institute
Miami, FL
Rosalinda Alvarado, MD, FACS
RUSH University Medical Group
Oak Park, IL
Dalliah Black, MD, FACS
Mayo Clinic
Rochester, MN
Daniela Cocco, MD, FACS
Valleywise Comprehensive Health Center
Phoenix, AZ
Tammy De La Melena, MD, FACS
Compass Oncology
Tigard, OR
Aye Moe Thu Ma, MD
Oakland, CA
Tanya W. Moseley, MD, DBA, FACR, FSBI
MD Anderson
Houston, TX
Emil J. Fernando, MD, FACS
Allegheny Health Network
Pittsburgh, PA
Gary Ko, MD
Mount Sinai Hospital
Toronto, CA
  1. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R, Luini A, Viale G, Cassano E, Peradze N, Toesca A, Massari G, Sacchini V, Munzone E, Leonardi MC, Cattadori F, Di Micco R, Esposito E, Sgarella A, Cattaneo S, Busani M, Dessena M, Bianchi A, Cretella E, Ripoll Orts F, Mueller M, Tinterri C, Chahuan Manzur BJ, Benedetto C, Veronesi P; SOUND Trial Group. JAMA Oncol. 2023 Nov 1;9(11):1557-1564. doi:10.1001/jamaoncol.2023.3759. PMID: 37733364
  2. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD, Le-Petross HT, Giuliano AE, Van Zee KJ, Hunt KK, Hahn OM, Carey LA, Partridge AH. J Clin Oncol. 2023 Jun 10;41(17):3184-3193. doi: 10.1200/JCO.22.02553. Epub 2023 Mar 28. PMID: 36977292
  3. Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304. Mamounas, T. Bandos, H., White, J. SABCS 2023
  4. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA. Jagsi R, Griffith KA, Harris EE, Wright JL, Recht A, Taghian AG, Lee L, Moran MS, Small W Jr, Johnstone C, Rahimi A, Freedman G, Muzaffar M, Haffty B, Horst K, Powell SN, Sharp J, Sabel M, Schott A, El-Tamer M. J Clin Oncol. 2024 Feb 1;42(4):390-398. doi: 10.1200/JCO.23.02270. Epub 2023 Dec 7. PMID: 38060195
  5. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. N Engl J Med. 2023 May 4;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. PMID: 37133584
  6. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. PMID: 35139274
Use the link below to view disclosure information for all individuals and groups involved in the planning, implementation, and evaluation of this educational activity.
View Disclosure Information (pdf)